Martin F Bachmann

This inventor holds 27 USPTO granted patents and 33 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Vaccine Development. Top assignees: Cytos Biotechnology Ag, Cytis Biotechnology Ag, Intercell Ag. Active years: 2005-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin F Bachmann. Retrieved from https://idiyas.com/inventor/martin-f-bachmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 33)

% Patents Active = 14.8

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 4)

Average Co-Inventor Count = 3.3

ph-index = 12

Forward Citations = 398(Granted Patents)

Location History:

Seuzach, CH (2005 - 2013)
Winterthur, CH (2005 - 2018)

Company Filing History:

24 out of 31

Cytos Biotechnology Ag

patents

1 out of 1

Cytis Biotechnology Ag

where one patent can have more than one assignee

Years Active: 2005-2018

Loading Chart...

Areas of Expertise:

Virus-Like Particles

Immunostimulatory Substances

Antigen Arrays

Monoclonal Antibodies

Peptide-Carrier Conjugates

Nucleic Acid Packaging

Hypersensitivity Treatment

Bone Disease Treatment

Allergen Conjugates

Molecular Antigen Arrays

Interleukin-1 Muteins

Gastric Inhibitory Polypeptide

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9950055 - Packaging of immunostimulatory substances into virus-like particles: method of preparation and use (2018-04-24),

2. 8691209 - Packaging of immunostimulatory substances into virus-like particles: method of preparation and use (2014-04-08),

3. 8574564 - Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity (2013-11-05),

4. 8460670 - Fully human influenza M2 specific antibodies (2013-06-11),

5. 8449874 - Interleukin-1 muteins linked to virus-like particles to treat IL-1 associated diseases (2013-05-28),

6. 8344111 - Human monoclonal nicotine specific antibodies (2013-01-01),

7. 8187607 - Hapten-carrier conjugates and uses thereof (2012-05-29),

8. 7959928 - VLP-antigen conjugates and their uses as vaccines (2011-06-14),

9. 7959924 - Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof (2011-06-14),

10. 7785873 - Antigen arrays for treatment of bone disease (2010-08-31),

11. 7767212 - CAT allergen conjugates and uses thereof (2010-08-03),

12. 7666408 - Angiotensin peptide-carrier conjugates and uses thereof (2010-02-23),

13. 7572451 - Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof (2009-08-11),

14. 7537767 - Melan-A- carrier conjugates (2009-05-26),

15. 7517520 - Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use (2009-04-14),

Title: Martin F. Bachmann: An Innovator in Immunology

Introduction: Martin F. Bachmann, located in Seuzach, Switzerland, is an accomplished inventor with an impressive portfolio of 27 patents. His work primarily focuses on immunology and the development of innovative methods for enhancing immune responses through novel approaches involving virus-like particles (VLPs).

Latest Patents: One of Bachmann's latest patents involves the packaging of immunostimulatory substances into virus-like particles. This invention describes a method of preparation and use for loading VLPs with specific DNA oligonucleotides that contain non-methylated C and G sequences (CpGs). These CpG-VLPs have shown to be significantly more immunogenic compared to their CpG-free counterparts. The resulting immune response is characterized by enhanced B and T cell activity. This advancement could lead to effective vaccinations against a variety of health challenges, such as allergies, tumors, and chronic viral diseases.

Career Highlights: Throughout his career, Martin F. Bachmann has made significant contributions to the field of biotechnology. He has worked at notable companies, including Cytos Biotechnology AG and Novartis Pharma AG, where he has played a crucial role in driving forward cutting-edge research and innovative product development.

Collaborations: Bachmann has collaborated with other esteemed professionals in the field, including Patrik Maurer and Alain Tissot. These partnerships have fostered knowledge sharing and contributed to the success of his innovative projects.

Conclusion: Martin F. Bachmann exemplifies dedication and ingenuity in the realm of immunology. With his numerous patents and collaborative efforts, he continues to pave the way for groundbreaking advancements that hold the potential to transform treatments and preventative measures in healthcare. His work with virus-like particles demonstrates a leading-edge approach to enhancing immunogenicity and offers exciting possibilities for future vaccine development.

Profile summary based on public USPTO records.